ArticleEuropean journal of cancer (Oxford, England : 1990)2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
Article in European journal of cancer (Oxford, England : 1990), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.Melanoma research · 2019Pooled it
- Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms.The Journal of dermatology · 2026Review
- Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.Journal for immunotherapy of cancer · 2026Article
- Harnessing Vδ1Frontiers in immunology · 2026Review
- Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising "Off-the-Shelf" Immunotherapy Approach.Cancers · 2025Article
- Cellular and molecular characterization of γδ T cells in peripheral blood from patients with metastases from cutaneous and uveal melanoma.Frontiers in immunology · 2025Article
- Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?European journal of immunology · 2025Review
- Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- γδ T cells as critical anti-tumor immune effectors.Nature cancer · 2024Review
- γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment.Journal of translational medicine · 2024Review
- Landscape of unconventional γδ T cell subsets in cancer.Molecular biology reports · 2024Review
- Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.Cancer immunology, immunotherapy : CII · 2024Article
- Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy.Frontiers in immunology · 2024Review
- Potential of gamma/delta T cells for solid tumor immunotherapy.Frontiers in immunology · 2024Review
- Controversial role of γδ T cells in colorectal cancer.American journal of cancer research · 2024Review
- Exhausted intratumoral Vδ2Nature immunology · 2023Article
- Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.Frontiers in oncology · 2023Article
- Deep characterization of human γδ T cell subsets defines shared and lineage-specific traits.Frontiers in immunology · 2023Article
- A close look at current γδ T-cell immunotherapy.Frontiers in immunology · 2023Review
- Oncogenic and immunological values of RBM34 in osteosarcoma and its pan-cancer analysis.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analysed the frequencies of peripheral γδ T-cells, including their most prominent subsets (Vδ1+ and Vδ2+ cells) and differentiation states in 109 melanoma patients and 109 healthy controls. We additionally analysed the impact of γδ T-cells on overall survival (OS) calculated from the first dose of ipilimumab in melanoma patients. Higher median frequencies of Vδ1+ cells and lower median frequencies of Vδ2+ cells were identified in patients compared to healthy subjects (Vδ1+: 30% versus 15%, Vδ2+: 39% versus 64%, both p < 0.001). Patients with higher frequencies of Vδ1+ cells (≥30%) had poorer OS (p = 0.043) and a Vδ1+ differentiation signature dominated by late-differentiated phenotypes. In contrast, higher frequencies of Vδ2+ cells (≥39%) were associated with longer survival (p = 0.031) independent of the M category or lactate dehydrogenase level. Patients with decreasing frequencies of Vδ2+ cells under ipilimumab treatment had worse OS and a lower rate of clinical benefit than patients without such decreases. Therefore, we suggest frequencies of both Vδ1+ and Vδ2+ cells as candidate biomarkers for outcome in melanoma patients following ipilimumab. Further studies are needed to validate these results and to clarify whether they represent prognostic associations or whether γδ T-cells are specifically and/or functionally linked to the mode of action of ipilimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.